Healthcare
4D Molecular Therapeutics, Inc.(FDMT)
Live Price
Offline$9.66
+2.55% today
1Y Change
+156.23%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $540.00M
- Revenue Growth
- +230194.6%
- EPS Growth
- +18.8%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
4D Molecular Therapeutics, Inc. (FDMT) is a Healthcare stock with a market cap of $540.00M and listed on NASDAQ. The stock last traded around $9.66 and up 156.2% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +230194.6%, EPS growth of +18.8%, a dividend yield of 0.0%. What stands out right now is revenue +230194.6%, EPS +18.8%, free cash flow +21.2% with operating margin -187.2% and ROIC -30.2%. Valuation sits in the middle of the pack at price/sales 6.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines FDMT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+230194.6% vs +7.6% peer median
Operating Margin
Below sector median
-187.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +230194.6% and EPS at +18.8%, with operating margin around -187.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -6.7% | -11.4% | -10.0% |
2026 Mar 18, 2026 | +181.1% | +4.9% | +15.4% | +17.5% |
2025 Nov 10, 2025 | +1.0% | +6.2% | +7.7% | +3.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
FDMT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
FDMT Max Drawdown
-41.40%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FDMT and SPY.
Company Overview
4D Molecular Therapeutics, Inc.
NASDAQ Global Select
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
- Leadership
- David H. Kirn
- IPO Date
- Dec 11, 2020
- Employees
- 227
- Street Address
- 5858 Horton Street
- Mailing
- EmeryVille, CA, 94608
- Region
- EmeryVille, CA, US
- Reporting Currency
- USD
- Investor Line
- 510 505 2680
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 6.4
- Price/Book
- 1.2
Growth
- Revenue
- +230194.6%
- EPS
- +18.8%
- Free Cash Flow
- +21.2%
Profitability
- Gross Margin
- -14.0%
- Operating Margin
- -187.2%
- Net Margin
- -164.4%
- ROE
- -31.7%
- ROIC
- -30.2%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 9.39
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.